The prognostic, diagnostic and predictive value of the HER2 biomarker has been established for breast, gastric, and gastro-esophageal junction cancers. Over the past two decades, therapies such as Trastuzumab, Lapatinib and Trastuzumab-duocarmazine have been developed to treat these cancers, but their use and efficacy depend on accurate classification of the HER2 status of the tumor.

Differences in HER2 expression among these cancers and tissue types requires expert analysis to score and interpret, and Discovery’s Global Tissue Biomarker Services Europe has led the field in establishing methodological guidelines to meet this need. The Discovery Biomarker Academy offers global pathology biomarker training services with experts instructing on cutting-edge platforms and current methods for IHC and in situ hybridization.

Discovery’s Global Tissue Biomarker Services have supported assay development, validation and global clinical trial testing by providing expeditious and high-quality results, which are crucial to the success of drug and companion diagnostic development programs and are fit for any stage of research and development.